News | Proton Therapy | June 22, 2020

Orfit Aerial Couch Top for Proton Therapy Validated by Mevion Medical Systems

Mevion Medical Systems and Orfit Industries announced that the Aerial Couch Top is validated for use on the Mevion S250 Series Proton Therapy Systems.

June 22, 2020 —  Mevion Medical Systems and Orfit Industries announced that the Aerial Couch Top is validated for use on the Mevion S250 Series Proton Therapy Systems.

“Mevion is committed to providing customizable and complementary immobilization products to our customers and we are excited to partner with Orfit to add the Aerial Couch Top and accessories to our proton therapy systems,” said Ying Xiong, vice president of product management at Mevion Medical Systems.

The Aerial Couch Top combines precise and reproducible immobilization with homogeneity over the entire treatment area. With no rails or other obstructions below the extension, this recently US FDA cleared couch top minimizes the air gap, improving penumbra and plan quality. Aerial extensions are available for extracranial treatment and brain, head, and neck treatments when used with Orfit HP PRO masks. The use of 3-points single layer HP PRO masks can reduce target margins to 1 mm.

“The design of the Aerial is in line with the highest technical and safety standards, without being overly complex, so that it helps assure the best possible clinical outcome for patients. This couch top perfectly pairs with advanced proton therapy systems, such as MEVION S250i,” stated Emilie Cuypers, product manager radiation oncology at Orfit.

Together, we are pleased to make this entirely new couch top available as of September 2020 to current and future Mevion operated proton therapy centers.

For more information: www.mevion.com

Related Content

News | Radiation Therapy | May 06, 2021
May 6, 2021 — Individuals living with severe...
Research finds that a commonly used risk-prediction model for lung cancer does not accurately identify high-risk Black patients who could benefit from early screening

Getty Images

News | Lung Imaging | May 05, 2021
May 5, 2021 — Lung cancer is the third most common cance
The emergence of #therapeutic #radiopharmaceuticals and its adoption in #cancer care provide one more weapon in combating cancer

Getty Images

Feature | Radiation Oncology | May 04, 2021 | By Vinay Shivaprasad
The term nuclear medicine is associated with the diag
Despite receiving high radiation doses to their tumors, lung cancer patients treated with technique that spares a large part of the esophagus did not develop severe inflammation of the esophagus

Getty Images

News | Lung Imaging | April 30, 2021
April 30, 2021 — For many patients with localized lung cance...
#prostatecancer During the first wave of the corona pandemic, 36 percent fewer men were diagnosed with prostate cancer in Sweden than in previous years.

Getty Images

News | Prostate Cancer | April 30, 2021
April 30, 2021 — During the first wave of the corona pandemic, 36 percent fewer men were diagnosed with prostate canc
A 63-year-old multiple #myeloma patient, with skeletal pain. New #FDG avid axillary #lymphadenopathy 62 days (9 weeks) after second #mRNA #vaccination dose. Image used with permission of the Radiological Society of North America (#RSNA)

A 63-year-old multiple myeloma patient, with skeletal pain. New FDG avid axillary lymphadenopathy 62 days (9 weeks) after second mRNA vaccination dose. Image used with permission of the Radiological Society of North America (RSNA)

Feature | Coronavirus (COVID-19) | April 29, 2021 | By Melinda Taschetta-Millane
A phase 1 clinical trial led by investigators at the University of Chicago Medicine testing the effects of stereotactic body radiotherapy for treating multiple metastases has determined that treatments used for single tumors can also be safely used for treating patients with multiple metastases.

Image courtesy of Accuray

News | Stereotactic Body Radiation Therapy (SBRT) | April 23, 2021
April 23, 2021 — A phase 1 clinical trial led by investigators at the...
A Norwegian study for the first time reveals benefit of the #PARP inhibitor #Olaparib in patients with early #breastcancer not harboring germline mutations

Getty Images

News | Radiation Therapy | April 22, 2021
April 22, 2021 — Targeted therapy in early stages of breas...